Wall Street brokerages expect Guardant Health Inc (NASDAQ:GH) to report sales of $24.57 million for the current quarter, according to Zacks. Four analysts have made estimates for Guardant Health’s earnings. The highest sales estimate is $26.58 million and the lowest is $20.99 million. The company is expected to announce its next quarterly earnings results on Monday, February 18th.
On average, analysts expect that Guardant Health will report full-year sales of $83.43 million for the current financial year, with estimates ranging from $82.50 million to $84.01 million. For the next financial year, analysts forecast that the company will report sales of $116.02 million, with estimates ranging from $111.69 million to $120.30 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that follow Guardant Health.
Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Monday, November 19th. The company reported ($1.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.29) by ($1.65). The firm had revenue of $21.70 million for the quarter, compared to the consensus estimate of $17.44 million. The firm’s revenue was up 95.5% compared to the same quarter last year.
Shares of GH traded up $1.40 during trading hours on Friday, hitting $42.94. 380,395 shares of the stock were exchanged, compared to its average volume of 442,587. Guardant Health has a fifty-two week low of $27.04 and a fifty-two week high of $49.55.
Guardant Health Company Profile
Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.
See Also: Investing in Dividend Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.